Liraglutide: A phase II, randomized, double-blinded, placebo-controlled trial of Liraglutide in Parkinson’s disease (Extension 2)
Cure Parkinson's
Cedars-Sinai Medical Center
Extension to MT011. See above.
6.1 Pharmaceuticals